Kevin Balthaser - Mar 1, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Financial Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Mar 1, 2023
Transactions value $
-$23,579
Form type
4
Date filed
3/3/2023, 07:09 PM
Previous filing
Feb 3, 2023
Next filing
Sep 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +1.48K +210.71% 2.18K Mar 1, 2023 Direct F1
transaction ACRS Common Stock Options Exercise +1.1K +50.57% 3.28K Mar 1, 2023 Direct F1
transaction ACRS Common Stock Options Exercise +2.38K +72.52% 5.65K Mar 1, 2023 Direct F1
transaction ACRS Common Stock Sale -$12.3K -1K -17.7% $12.29 4.65K Mar 2, 2023 Direct F2, F3
transaction ACRS Common Stock Options Exercise +1.5K +32.26% 6.15K Mar 2, 2023 Direct F1
transaction ACRS Common Stock Sale -$11.3K -894 -14.54% $12.63 5.26K Mar 3, 2023 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -1.48K -100% $0.00* 0 Mar 1, 2023 Common Stock 1.48K Direct F1, F6
transaction ACRS Restricted Stock Units Options Exercise $0 -1.1K -33.33% $0.00 2.2K Mar 1, 2023 Common Stock 1.1K Direct F1, F7
transaction ACRS Restricted Stock Units Options Exercise $0 -2.38K -25% $0.00 7.13K Mar 1, 2023 Common Stock 2.38K Direct F1, F8
transaction ACRS Restricted Stock Units Options Exercise $0 -1.5K -50% $0.00 1.5K Mar 2, 2023 Common Stock 1.5K Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.96 to $12.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.
F5 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.47 to $12.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F7 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F8 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F9 The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.